{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.7","upperLimit":"24.2","value":"17.7"},{"groupId":"OG001","lowerLimit":"14.2","upperLimit":"20.9","value":"17.9"},{"groupId":"OG002","lowerLimit":"18.2","upperLimit":"23.0","value":"20.1"},{"groupId":"OG003","lowerLimit":"15.8","upperLimit":"43.7","value":"27.2"},{"groupId":"OG004","lowerLimit":"28.2","upperLimit":"100","value":"47.0"},{"groupId":"OG005","lowerLimit":"13.3","upperLimit":"21.0","value":"18.8"},{"groupId":"OG006","lowerLimit":"17.9","upperLimit":"35.4","value":"26.0"},{"groupId":"OG007","lowerLimit":"15.1","upperLimit":"42.7","value":"26.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"AMG 224 Conjugated Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"22.3","value":"14.5"},{"groupId":"OG001","lowerLimit":"14.8","upperLimit":"17.3","value":"15.9"},{"groupId":"OG002","lowerLimit":"12.4","upperLimit":"15.5","value":"14.3"},{"groupId":"OG003","lowerLimit":"12.4","upperLimit":"30.0","value":"18.8"},{"groupId":"OG004","lowerLimit":"12.9","upperLimit":"37.7","value":"25.5"},{"groupId":"OG005","lowerLimit":"9.13","upperLimit":"18.8","value":"13.7"},{"groupId":"OG006","lowerLimit":"10.9","upperLimit":"30.9","value":"20.9"},{"groupId":"OG007","lowerLimit":"11.2","upperLimit":"22.8","value":"16.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"title":"AMG 224 Conjugated Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.1","upperLimit":"23.2","value":"16.5"},{"groupId":"OG001","lowerLimit":"13.5","upperLimit":"18.2","value":"15.8"},{"groupId":"OG002","lowerLimit":"15.2","upperLimit":"19.8","value":"17.8"},{"groupId":"OG003","lowerLimit":"14.8","upperLimit":"38.0","value":"23.9"},{"groupId":"OG004","lowerLimit":"25.7","upperLimit":"72.8","value":"40.5"},{"groupId":"OG005","lowerLimit":"15.2","upperLimit":"18.3","value":"16.8"},{"groupId":"OG006","lowerLimit":"15.5","upperLimit":"40.7","value":"24.6"},{"groupId":"OG007","lowerLimit":"12.9","upperLimit":"34.6","value":"26.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"title":"Total Anti-BCMA Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.07","upperLimit":"20.5","value":"13.4"},{"groupId":"OG001","lowerLimit":"12.9","upperLimit":"14.3","value":"13.4"},{"groupId":"OG002","lowerLimit":"8.92","upperLimit":"12.6","value":"11.4"},{"groupId":"OG003","lowerLimit":"9.10","upperLimit":"25.8","value":"15.8"},{"groupId":"OG004","lowerLimit":"9.94","upperLimit":"32.6","value":"22.1"},{"groupId":"OG005","lowerLimit":"9.29","upperLimit":"16.2","value":"11.4"},{"groupId":"OG006","lowerLimit":"10.1","upperLimit":"34.6","value":"22.4"},{"groupId":"OG007","lowerLimit":"11.6","upperLimit":"24.8","value":"18.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"Total Anti-BCMA Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"20400000","upperLimit":"21300000","value":"20800000"},{"groupId":"OG003","lowerLimit":"6310000","upperLimit":"131000000","value":"53300000"},{"groupId":"OG004","lowerLimit":"2190000","upperLimit":"24300000","value":"9310000"},{"groupId":"OG005","lowerLimit":"3180000","upperLimit":"5790000","value":"4360000"},{"groupId":"OG006","lowerLimit":"3740000","upperLimit":"9350000","value":"6100000"},{"groupId":"OG007","lowerLimit":"2160000","upperLimit":"10600000","value":"5620000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"DM1 after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"18700000","upperLimit":"18700000","value":"18700000"},{"groupId":"OG002","lowerLimit":"13500000","upperLimit":"173000000","value":"69800000"},{"groupId":"OG003","lowerLimit":"5860000","upperLimit":"21700000","value":"11300000"},{"groupId":"OG004","lowerLimit":"2850000","upperLimit":"7270000","value":"5060000"},{"groupId":"OG005","lowerLimit":"2470000","upperLimit":"3930000","value":"2990000"},{"groupId":"OG006","lowerLimit":"3660000","upperLimit":"8290000","value":"5970000"},{"groupId":"OG007","lowerLimit":"2080000","upperLimit":"4960000","value":"3480000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"title":"DM1 after Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"CL of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was determined.","dispersionType":"Full Range","groups":[{"description":"Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG000","title":"Dose Exploration: AMG 224 Dose A"},{"description":"Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG001","title":"Dose Exploration: AMG 224 Dose B"},{"description":"Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG002","title":"Dose Exploration: AMG 224 Dose C"},{"description":"Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG003","title":"Dose Exploration: AMG 224 Dose D"},{"description":"Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG004","title":"Dose Exploration: AMG 224 Dose E"},{"description":"Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG005","title":"Dose Exploration: AMG 224 Dose F"},{"description":"Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG006","title":"Dose Exploration: AMG 224 Dose G"},{"description":"All participants in Dose Expansion who had prior treatment or no prior treatment with a CD38-targeting antibody were administered the MTD of AMG 224 identified in the dose escalation as 3 mg/kg. AMG 224 was administered as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG007","title":"Dose Expansion: AMG 224 3 mg/kg"}],"paramType":"MEAN","populationDescription":"The PK parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated.","reportingStatus":"POSTED","timeFrame":"AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)","title":"Clearance (CL) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1","type":"SECONDARY","unitOfMeasure":"mL/hr"}